Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 17;14(14):3472. doi: 10.3390/cancers14143472

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Comparison of smoking habit measured in pack-year among the three BRAF functional classes of alterations, showing a significantly greater pack-year value in patients harboring class 2 and class 3 BRAF alterations as compared to those with class 1 alterations (A). Consistently, tumor mutational burden (TMB) was significantly higher in patients harboring class 2 and class 3 BRAF alterations as compared to those with class 1 alterations (B). No statistically significant difference in terms of median TMB was found between patients harboring BRAF alterations of known functional class and all patients with NSCLC in the cBioPortal cohort. Kaplan–Meier of overall survival of patients with distinct BRAF alteration classes shows no statistically significant differences between classes in the POPLAR/OAK cohort (C), regardless of the treatment type (docetaxel or atezolizumab) (D). No statistically significant differences were found in terms of overall survival in patients harboring different classes of BRAF alterations in the cBioPortal cohort (E). TMB: tumor mutational burden; NSCLC: non-small cell lung cancer.